Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Chlamydia Market Growth in 2025?
The market size for chlamydia has seen robust growth in the past few years. It is predicted to increase from $2.97 billion in 2024 to $3.23 billion in 2025, marking a compound annual growth rate (CAGR) of 9.1%. Factors contributing to this growth in the historical period include an uptick in sexual health education initiatives, greater demand for prompt diagnostic tests, a surge in the requirement for affordable, scalable sexually transmitted infection diagnostics, the evolution of telemedicine, and heightened emphasis on precision medicine.
What Is the Forecast for the Chlamydia Market Size Through 2029?
Expect substantial advancements in the chlamydia market within the next few years as it is projected to expand to a staggering $4.53 billion by 2029. This represents a compound annual growth rate (CAGR) of 8.8%. This predicted incline during the forecast period is primarily a result of the rising incidence rate of chlamydia, heightened public consciousness, an increase in point-of-care testing alternatives, escalating numbers of sexually transmitted diseases, and a surge in research and development investments. The key trends to watch during the forecast period include a movement towards point-of-care testing, breakthroughs in molecular diagnostics, a priority shift to preventative healthcare, merging of artificial intelligence (AI) with diagnostics, and the advancement towards high-throughput screening platforms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp
What are the Key Market Players in Chlamydia Market and How They’re Evolving?
Major companies operating in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, Laxai Pharma Ltd.
What Are the Primary Growth Drivers in the Chlamydia Market?
The escalation in the occurrence of sexually transmitted diseases (STDs) is anticipated to fuel the development of the chlamydia market. STDs, including chlamydia, gonorrhea, and HIV, are infections transferred primarily through sexual contact. The rising numbers of these diseases can be traced back to factors like reduced condom usage, lack of understanding, inadequate healthcare accessibility and the growing popularity of dating apps encouraging multiple sexual partnerships. Treatments for chlamydia are critical in containing the spread of STDs by eradicating the infection, forestalling complications, and diminishing the possibility of passing the disease to sexual partners. For instance, data from the National Association of County and City Health Officials in June 2024 showed that in 2022, there were over 2.5 million syphilis, gonorrhea, and chlamydia cases reported in the U.S., with syphilis showing an 80% increase and congenital syphilis rising by 937%. Reporting indicates a 31% increase from 2021 to 2022, with 3,755 cases of congenital syphilis. Consequently, this rising prevalence of sexually transmitted diseases bolsters the growth of the chlamydia market. The chlamydia market’s progress is also being augmented by the expansion of telemedicine services. These services encompass the use of various digital communication platforms like video calls, mobile apps, and remote monitoring tools to deliver healthcare services from a distance. This expansion can be accredited to progress in digital health technologies, growing access to high-speed internet, and increasing demand for remote healthcare options. Chlamydia patients significantly benefit from telemedicine as it allows them to avail of remote consultations, secure prescriptions, and maintain privacy during follow-up care, which makes the treatment procedure convenient and enhances adherence to timely treatment. For instance, the US-based non-profit organization, FAIR Health Inc., reported a 7.3% national rise in the use of telehealth, increasing from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Additionally, Rock Health, a US-based venture capital organization, indicated in February 2023 that according to their 2022 study, 80% of those surveyed claimed to have used telemedicine at some stage in their lives, indicating an 8-point percentage rise from 72% in 2021. Hence, the chlamydia market growth is propelled by the telemedicine services expansion.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp
What Are the Leading Segments in the Global Chlamydia Industry?
The chlamydia market covered in this report is segmented –
1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture
2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)
3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection
4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot
5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)
What Are the Key Market Trends in the Chlamydia Industry?
Leading companies in the chlamydia market are striving to develop fully automated systems to increase diagnostic precision, minimise human errors, and enhance test efficiency. A fully automated system operates without human interaction, usually employing sensors, control mechanisms, and artificial intelligence to execute tasks independently. For instance, BD (Becton, Dickinson and Company), a medical device firm based in the US, introduced the BD COR MX/PX System in May 2022. The first test available on this new system will be the BD CTGCTV2 molecular assay. It identifies the top three non-viral sexually transmitted diseases (STIs)—chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), and trichomonas vaginalis (TV)—with a single test. These STIs can result in numerous adverse health effects for patients, such as complications during pregnancy and an increased likelihood of acquiring HIV.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report
What Is the Regional Outlook for the Chlamydia Market?
North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21138
This Report Delivers Insight On:
1. How big is the chlamydia market, and how is it changing globally?
2. Who are the major companies in the chlamydia market, and how are they performing?
3. What are the key opportunities and risks in the chlamydia market right now?
4. Which products or customer segments are growing the most in the chlamydia market?
5. What factors are helping or slowing down the growth of the chlamydia market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model